Abstract
Abstract Current management of pediatric brain tumor patients relies on imaging as the only non-invasive tool available for monitoring therapeutic response and tumor progression. Results are often inconclusive and unable to capture biological changes that presage progression on imaging. Circulating miRNA provides an attractive non-invasive platform because miRNA’s essential role in regulating gene expression, stability in bio-fluids, selective over-expression in tumors, and subsequent active release from tumors into the extracellular environment. We aimed to establish the prognostic and monitoring value of miRNA biomarkers for pediatric brain tumors. We performed miRNA profiling of CSF (n=33) and plasma (n=53) samples across a cohort of 54 pediatric brain tumors from 6 histologies (low grade glioma, ependymoma, germ cell tumor, medulloblastoma, atypical teratoid rhabdoid tumor and high-grade glioma). We utilized unsupervised consensus clustering, differential expression, and machine learning methods to explore miRNA biomarkers. Plasma miRNA signatures were correlated with WHO Grade while CSF signatures revealed a correlation with leptomeningeal disease and higher disease burden (p<0.05). The expression of circulating miRNA revealed histology-specific signatures for low grade glioma, medulloblastoma and germinoma in plasma and CSF (p<0.05). We identified miRNA signatures of significant translational value: (1) A medulloblastoma specific miRNA in CSF can serve as a potential biomarker for tumor monitoring (medulloblastoma specificity was confirmed in independent tissue-based dataset); (2) Pilocytic astrocytoma can be distinguished from high grade glioma in CSF; (3) Most intriguingly, in plasma, miRNA expression identified pilocytic astrocytoma that had relapsed in several months after initial intervention (p<0.05). These results support circulating miRNA in plasma and CSF as biomarkers of diverse clinical diagnostic and prognostic measures. Further utilization of this approach provides unique platforms to inform liquid biopsy-based management in the clinical setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
